We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+62.61%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
+$385M
Cap. Flow
+$46M
Cap. Flow %
3.94%
Top 10 Hldgs %
67.93%
Holding
74
New
28
Increased
5
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$176M
2
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$22.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$13.9M
4
ABCL icon
AbCellera Biologics
ABCL
+$13.7M
5
COGT icon
Cogent Biosciences
COGT
+$13.7M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$72.5M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$46.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$38.6M
4
TGTX icon
TG Therapeutics
TGTX
+$30.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EAR
51
DELISTED
Eargo, Inc. Common Stock
EAR
$2.24M 0.19%
+2,500
New +$2.11M
OPT
52
DELISTED
Opthea Limited American Depositary Shares
OPT
$1.79M 0.15%
+160,000
New +$2.02M
PLRX icon
53
Pliant Therapeutics
PLRX
$65M
$1.74M 0.15%
76,426
-60,289
-44% -$1.51M
TVTX icon
54
Travere Therapeutics
TVTX
$5.17B
$1.67M 0.14%
+61,152
New +$1.43M
CERE
55
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.66M 0.14%
+100,000
New +$1.3M
AMTI
56
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$1.32M 0.11%
+42,847
New +$1.36M
FSDC
57
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$1.1M 0.09%
100,000
– –
GBIO
58
DELISTED
Generation Bio
GBIO
$482K 0.04%
+1,700
New +$546K
CEREW
59
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$188K 0.02%
+33,333
New +$134K
CLDX icon
60
Celldex Therapeutics
CLDX
$2.94B
– –
-1,200,000
Closed -$17.8M
CYTK icon
61
Cytokinetics
CYTK
$10.6B
– –
-750,000
Closed -$16.2M
RAPT
62
DELISTED
RAPT Therapeutics
RAPT
– –
-3,888
Closed -$1M
RLAY icon
63
Relay Therapeutics
RLAY
$4B
– –
-100,000
Closed -$4.26M
SAGE
64
DELISTED
Sage Therapeutics
SAGE
– –
-250,000
Closed -$15.3M
SRPT icon
65
Sarepta Therapeutics
SRPT
$1.64B
– –
-275,000
Closed -$38.6M
NARI
66
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-50,000
Closed -$3.45M
AFIB
67
DELISTED
Acutus Medical Inc
AFIB
– –
-75,000
Closed -$2.23M
AKUS
68
DELISTED
Akouos Inc
AKUS
– –
-310,000
Closed -$7.09M
GBT
69
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-850,000
Closed -$46.9M
CHAQ.U
70
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
– –
-200,000
Closed -$2.11M
PAND
71
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-450,000
Closed -$5.16M
LSACU
72
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
– –
-400,000
Closed -$5.44M
ARYBU
73
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
– –
-100,000
Closed -$1.1M
INBX
74
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-311,578
Closed -$5.61M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q4 2020 Portfolio in Review

As of Q4 2020, Logos Global Management held 74 positions worth $1.17B, up 49% from $781M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Logos Global Management deployed $46M of net new capital in Q4 2020, opening 28 new positions and adding to 5 existing holdings. Its largest new stake was Olema Pharmaceuticals: 3,743,875 shares worth $180M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $72.5M trimmed.

  • Logos Global Management's largest Q4 2020 buy was Olema Pharmaceuticals: 3,743,875 shares worth $180M.
  • Logos Global Management added most to Cogent Biosciences in Q4 2020, an estimated $13.7M increase.
  • Logos Global Management's biggest Q4 2020 reduction was Keros Therapeutics, cutting an estimated $72.5M.
  • Logos Global Management fully exited Global Blood Therapeutics, Inc. in Q4 2020, selling an estimated $46.9M.
  • Logos Global Management's ten largest holdings make up 68% of its $1.17B portfolio in Q4 2020.
  • Logos Global Management opened 28 new positions and closed 15 in Q4 2020.
  • Logos Global Management's portfolio value rose 49% quarter-over-quarter to $1.17B.

Based on Logos Global Management's 13F filing for Q4 2020, filed 16 Feb 2021.